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Dermatology Quality of Life Instruments: 
Sorting Out the Quagmire
the field of dermatology can take credit for improving the quality of patients’ lives. Many skin conditions affect patients in a 
multidimensional manner, ranging from emo-
tional to social interactions, symptoms, and func-
tional impairment. An example of one such skin 
condition is psoriasis, which has been shown to 
affect quality of life to an extent similar to that 
seen in other chronic diseases such as cancer, 
arthritis, hypertension, heart disease, diabetes, 
and depression (Rapp et al., 1999). Individuals 
with psoriasis report feeling self-conscious about 
their appearance, and they may have a poor self-
image. John Updike devoted a chapter, “At War 
with My Skin,” to psoriasis in Self-Consciousness 
(Updike, 1980). He wrote, “Strategies of con-
cealment ramify, and self-examination is end-
less”—the patient is continually inventing ways 
to hide the symptoms. Patients may experience 
symptoms such as itching and pain to the point 
that the basic daily functions of walking and 
sleeping are affected.
Quantifying the quality of life impact of skin 
conditions has been a relatively recent effort, 
stemming from a movement throughout medical 
science to capture the outcomes of intervention. 
Generic quality of life measures have been used 
by the medical community to measure the qual-
ity of life impact of general medical problems. 
For skin conditions, investigators have begun 
to use generic quality of life measures such as 
the Medical Outcome Study, Short Form (SF)-36 
(Ware and Sherbourne, 1992) and SF-12 (Ware 
et al., 1996), the Nottingham Health Profile 
(McEwen and McKenna, 1996), and the Sickness 
Impact Profile (Bergner et al., 1981).
Many skin-specific quality of life mea-
sures have now been developed, one of the 
first being the Dermatology Life Quality Index 
(DLQI), developed in the United Kingdom in 
1994 (Finlay and Khan, 1994). There are cur-
rently 11 skin-specific quality of life measures 
that pertain to adults, as found by the Working 
Group on Core Measures of the Burden of Skin 
Diseases (VanBeek et al., 2007). Although these 
generic measures have been tested rigorously 
for psychometric properties, it has become evi-
dent to researchers that they do not necessarily 
capture issues that are specific to patients with 
skin disease.
Even more sensitive than skin-specific quality 
of life measures are disease-specific measures, 
which are designed to capture issues related to 
the disease that even skin-specific instruments 
cannot. For instance, the RosaQoL (Nicholson et 
al., 2007), a recently published rosacea-specific 
quality of life instrument, captures such topics as 
avoiding certain foods or drinks and frequency 
of flushing. These issues are not posed in skin-
specific quality of life measures because they do 
not pertain to all skin conditions. As a result, dis-
ease-specific measures are generally even more 
sensitive to changes in disease status.
An additional problem with these quality of 
life measures found by the Working Group on 
Core Measures of the Burden of Skin Diseases 
and by Both et al. (2007, this issue) is that there 
is a lack of standardization in definitions, con-
ceptualizations, and psychometric testing. 
Although there is consensus that quality of life 
incorporates the perception of physical symp-
toms, effects on daily role function, and psy-
chological impact, there is much disagreement 
and confusion about precise definitions, with 
researchers often using the same term (quality 
of life) to mean very different things. Moreover, 
widely varying procedures have been used in 
the initial development of quality of life mea-
sures for skin disease. The amount and qual-
ity of psychometric testing and validation also 
differ widely across instruments. Finally, an 
awareness of cultural differences is crucial 
when instruments are developed outside the 
country where the instrument is to be used. For 
instance, the Working Group on Core Measures 
of the Burden of Skin Diseases reported fewer 
than half of the instruments that they evaluated 
were initially developed in the United States. 
Instruments developed in other countries, 
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such as the United Kingdom, may have implications for the 
appropriateness of the wording of specific items and thus 
may have limited applicability in the United States and vice 
versa. There is a need for domestic application and testing of 
those instruments developed outside the country of usage.
Both et al. (2007, this issue) have taken a first step toward 
evaluating the generic quality of life instruments applied to 
dermatology, as well as the dermatology-specific quality 
of life measures. Their criteria for evaluation were adapted 
from existing guidelines and included a conceptual and 
measurement model, reliability, validity, responsiveness, 
item functioning, meaning of scores, administrative burden, 
respondent burden, and availability of alternative forms and 
of cultural and language adaptations. Using these criteria, 
they were able to make several recommendations regarding 
the best instruments to use. This approach paves the way for 
future applications.
As more therapies are developed for skin disease, there 
will be a need for highly sensitive instruments to demonstrate 
responsiveness in quality of life, and the most sensitive instru-
ments will be disease-specific. Although Both et al. (2007) did 
not evaluate disease-specific instruments, the Working Group 
found 15 for adults and 2 for children. With an increasing 
need for disease-specific measures, more investigators will 
be required to develop such instruments. The criteria applied 
by Both et al. will set the stage for the expectations for these 
new instruments.
Journals should consider adopting these criteria for papers 
submitted for publication that describe new instruments. 
However, to expect that each new instrument will fulfill all 
12 of the criteria outlined by Both et al. may be unrealistic. 
I have thus proposed a division into minimal criteria, for 
newly developed instruments, and necessary criteria, which 
an instrument must further demonstrate to gain full credence 
and acceptability.
Minimal criteria for new instruments:
• Validity (content and construct)
• Interpretability (comparative data in different clinical 
populations)
• Reliability (internal consistency using Cronbach’s alpha 
and retest reliability using an intraclass coefficient)
• Structure (using factor analysis or item response theory)
• Responsiveness
• Brief response burden
• Acceptable administrative burden
Necessary criteria to establish an instrument:
• Interpretability (minimal clinically important difference)
• Floor and ceiling effects
• Having been tested for alternative forms of administration
• For translated instruments, having been translated 
according to guidelines
This division of criteria is based on one person’s experi-
ence, and obviously it must be evaluated in a consensus set-
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